News

The terms of the transaction were not disclosed. Oasis designs, develops, manufactures and sells pre-analytic tools for the collection, preservation, and transportation of saliva/oral fluids. Oasis’ focus is

This collaboration builds on positive proof of concept data published in the journal "Blood" demonstrating that ex vivo treatment of Tregs with TZ101 prior to administration is an

The investment syndicate includes existing investors, including BlueWater Angels, and new investors RBV Capital, ExSight Capital, and Santen Pharmaceutical. Earlier in 2015, RetroSense Therapeutics closed a $7m Series

The Viaskin Milk patch is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that can deliver biologically active compounds to the immune system through intact skin without

The primary endpoint for the study is the incidence of amenorrhea induced by four months of treatment with two dose levels of Proellex compared to placebo. In addition,

Obizur is indicated to treat bleeding episodes in adult patients with acquired haemophilia caused by antibodies to Factor VIII (FVIII), a life-threatening acute bleeding disorder. It will allow

The trial, called GBM Agile, will test various treatments depending on the molecular profile of a patient’s tumor. Treatments that do not work will be dropped from the

SCY-078 is being developed as both an oral and IV formulation to treat invasive and life-threatening fungal infections including candidemia and invasive aspergillosis. The study will assess the

Of the total amount, the company will spend €5bn for preclinical research through 2020, and €1.5bn will go to collaborations with external partners. The move is intended to